As Biotechnology businesses, Denali Therapeutics Inc. (NASDAQ:DNLI) and Ophthotech Corporation (NASDAQ:OPHT), are affected by contrast. This especially applies to their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Denali Therapeutics Inc. 132.72M 14.91 51.55M -1.45 0.00
Ophthotech Corporation N/A 0.00 N/A -1.40 0.00

In table 1 we can see Denali Therapeutics Inc. and Ophthotech Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Denali Therapeutics Inc. and Ophthotech Corporation.

Net Margins Return on Equity Return on Assets
Denali Therapeutics Inc. -38.84% -27.9% -24.7%
Ophthotech Corporation 0.00% 688.2% 97.3%

Liquidity

Denali Therapeutics Inc.’s Current Ratio and Quick Ratio are 12.1 and 12.1 respectively. The Current Ratio and Quick Ratio of its competitor Ophthotech Corporation are 13 and 13 respectively. Ophthotech Corporation therefore has a better chance of paying off short and long-term obligations compared to Denali Therapeutics Inc.

Institutional & Insider Ownership

The shares of both Denali Therapeutics Inc. and Ophthotech Corporation are owned by institutional investors at 84.5% and 65.6% respectively. About 0.1% of Denali Therapeutics Inc.’s share are held by insiders. On the other hand, insiders held about 0.2% of Ophthotech Corporation’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Denali Therapeutics Inc. -0.05% 15.48% 14.34% 22.14% 2.04% 6.53%
Ophthotech Corporation 6.85% 23.81% -12.36% -38.82% -42.86% 30%

For the past year Denali Therapeutics Inc.’s stock price has smaller growth than Ophthotech Corporation.

Summary

Ophthotech Corporation beats on 7 of the 9 factors Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *